| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2010.11.035 |
| P698 | PubMed publication ID | 21134452 |
| P2093 | author name string | Hui Wang | |
| Tao Li | |||
| Qin Wang | |||
| Xiang Gao | |||
| Wei Tu | |||
| Le Xiao | |||
| Kun Cai | |||
| Xiaojun Hou | |||
| Yuenan Liu | |||
| Maoren Tian | |||
| P2860 | cites work | Cross-protection against challenge by intravenous Escherichia coli verocytotoxin 1 (VT1) in rabbits immunized with VT2 toxoid | Q57676076 |
| Isolation and characterization of functional Shiga toxin subunits and renatured holotoxin | Q69543987 | ||
| Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections | Q24550740 | ||
| Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities | Q24646436 | ||
| Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I | Q24651553 | ||
| Crystal structure of the holotoxino from Shigella dysenteriae at 2.5 Å resolution | Q27729840 | ||
| Infection by Shiga toxin-producing Escherichia coli: an overview | Q33358878 | ||
| The role of Shiga-toxin-producing Escherichia coli in hemorrhagic colitis and hemolytic uremic syndrome | Q33363319 | ||
| Immunogenicity of a novel Stx2B-Stx1B fusion protein in a mice model of Enterohemorrhagic Escherichia coli O157:H7 infection | Q33384442 | ||
| Demonstration of RNA N-glycosidase activity of a Vero toxin (VT2 variant) produced by Escherichia coli O91:H21 from a patient with the hemolytic uremic syndrome | Q33397317 | ||
| Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2: Microbiological aspects | Q33397728 | ||
| Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections | Q33429817 | ||
| Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans | Q33505189 | ||
| Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model | Q33608157 | ||
| Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation | Q33883311 | ||
| Vaccination of pregnant dams with intimin(O157) protects suckling piglets from Escherichia coli O157:H7 infection | Q34121794 | ||
| Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1. | Q35012362 | ||
| Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains | Q35548775 | ||
| Identification of the Shiga toxin A-subunit residues required for holotoxin assembly | Q36124364 | ||
| Mutational analysis of the Shiga toxin and Shiga-like toxin II enzymatic subunits | Q36165342 | ||
| Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology | Q36872890 | ||
| Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies | Q36997934 | ||
| Importance of arginine at position 170 of the A subunit of Vero toxin 1 produced by enterohemorrhagic Escherichia coli for toxin activity. | Q38334562 | ||
| Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide | Q38350915 | ||
| Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. | Q39824053 | ||
| Enterotoxin-producing Escherichia coli O169:H41, United States | Q41781522 | ||
| Immunoprophylactic potential of cloned Shiga toxin 2 B subunit | Q43513677 | ||
| Mutations affecting the activity of the Shiga-like toxin I A-chain | Q44645523 | ||
| Physicochemical and immunochemical techniques predict the quality of diphtheria toxoid vaccines | Q44654194 | ||
| Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. | Q44838252 | ||
| Improved production of holotoxin Stx2 with biological activities by using a single-promoter vector and an auto-induction expression system | Q47775930 | ||
| Improved soluble expression and characterization of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli by using a PCR-synthesized gene and a Trx co-expression strain. | Q54394859 | ||
| Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. | Q54478105 | ||
| The role of tyrosine-114 in the enzymatic activity of the Shiga-like toxin I A-chain. | Q54648744 | ||
| Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2☆ | Q57563815 | ||
| P433 | issue | 5 | |
| P921 | main subject | Escherichia coli | Q25419 |
| P304 | page(s) | 946-952 | |
| P577 | publication date | 2010-12-04 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Enhanced immunogenicity of a novel Stx2Am-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection | |
| P478 | volume | 29 |
| Q27026551 | Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection |
| Q35801636 | Antibodies Directed against Shiga-Toxin Producing Escherichia coli Serotype O103 Type III Secreted Proteins Block Adherence of Heterologous STEC Serotypes to HEp-2 Cells |
| Q28087714 | Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype |
| Q37713379 | Comparative genomics and immunoinformatics approach for the identification of vaccine candidates for enterohemorrhagic Escherichia coli O157:H7. |
| Q92601613 | Development of a Gold Nanoparticle Vaccine against Enterohemorrhagic Escherichia coli O157:H7 |
| Q31165106 | Humoral immune response to Shiga Toxin 2 (Stx2) among Brazilian urban children with hemolytic uremic syndrome and healthy controls |
| Q90482717 | Immunization of mice with chimeric antigens displaying selected epitopes confers protection against intestinal colonization and renal damage caused by Shiga toxin-producing Escherichia coli |
| Q34596249 | Immunoproteomic analysis to identify Shiga toxin-producing Escherichia coli outer membrane proteins expressed during human infection. |
| Q53696162 | Intestinal Pathogenic Escherichia coli: Insights for Vaccine Development. |
| Q33428053 | Novel fusion antigen displayed-bacterial ghosts vaccine candidate against infection of Escherichia coli O157:H7 |
| Q44202411 | Novel fusion protein protects against adherence and toxicity of enterohemorrhagic Escherichia coli O157:H7 in mice |
| Q56568962 | OMV-based vaccine formulations against Shiga toxin producing Escherichia coli strains are both protective in mice and immunogenic in calves |
| Q27003178 | Pathogenicity, host responses and implications for management of enterohemorrhagic Escherichia coli O157:H7 infection |
| Q34375210 | Recent advances in understanding enteric pathogenic Escherichia coli. |
| Q33399468 | Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS). |
| Q36480155 | Vaccination with DNA Encoding Truncated Enterohemorrhagic Escherichia coli (EHEC) Factor for Adherence-1 Gene (efa-1') Confers Protective Immunity to Mice Infected with E. coli O157:H7. |
| Q35887055 | Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni. |
Search more.